Drug Trial Radar · NCT01004263
A Study to Evaluate the Safety and Tolerability of Rizatriptan for Long Term Treatment of Acute Migraine in Children and Adolescents (MK-0462-086 AM3)
Last checked: Nov 19, 2026Latest source record: Apr 22, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
674
Actual
Start
Dec 1, 2009
Primary completion
Apr 18, 2011
Study completion Apr 18, 2011
Sponsor
- Lead sponsor
- Organon and CoIndustry
- Sponsor type
- Industry
- First posted
- Oct 29, 2009
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 12 years, up to 17 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
To provide long term safety data for rizatriptan in children and adolescents. The primary hypothesis of the study is that rizatriptan is well tolerated in the long term treatment of acute migraine in pediatric patients age 12-17 years.
Conditions
- Acute Migraine With or Without Aura in Adolescents
Interventions
rizatriptan benzoateDrug
Single dose of 5 mg or 10 mg orally disintegrating tablet at onset of migraine attack
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Participants With Adverse Events (AEs) Within 24 Hours Post Any DoseTime frame: Up to 24 hours post dose
- Number of Participants With AEs Within 14 Days Post Any DoseTime frame: Up to 14 days post dose
- Number of Participants Discontinued From Study Due to AEs Occurring Within 24 Hours Post DoseTime frame: Up to 24 hours post dose
- Number of Participants Discontinued From Study Due to AEs Occurring Within 14 Days Post DoseTime frame: Up to 14 days post dose
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.